Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZN-457 in Healthy Volunteers
NCT05565768Phase 1Completed
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2022
- Primary completion
- Aug 2023
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in gout comparing HZN-457 with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESIs), Change from Baseline in Hemoglobin value at Day 85 and 9 more. Started Nov 2022; status: completed.
02
Drugs
HZN-457
03
Conditions
gout
Beyond the preview
Go deeper on NCT05565768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565768.